1,279 research outputs found
Türkçe-Makedonca Konuşma Kılavuzu 1, Türk transkripsiyonu ile / Турско-македонски разговорник 1, со турска транскрипција
No full textThe materials for the “ Turkish-Macedonian phrase book” were compiled during the Macedonian language classes with the students from Turkey. The author of the phrasebook, Marija Leontik has also classified and enlarged the materials. In order to enable the learners to self-study, the sentence is first given in Turkish language, than in Macedonian, then follows transcription of the Macedonian sentence. The aim is the beauty of the Turkish language to facilitate the learning of the beauty of the Macedonian language. Several professors (Simon Sazdov, Esen Bejzat, Halil Acikgjoz, Sevim Hilmioglu) reviewed the book in order to make it more useful and conformant with the criteria for this types of books
„Турско-македонски разговорник 1, со турска транскрипција“(“Turkish- Macedonian Phrasebook 1”)
No full textThe materials for the “ Turkish-Macedonian phrase book” were compiled during the Macedonian language classes with the students from Turkey. The author of the phrasebook, Marija Leontik has also classified and enlarged the materials. In order to enable the learners to self-study, the sentence is first given in Turkish language, than in Macedonian, then follows transcription of the Macedonian sentence. The aim is the beauty of the Turkish language to facilitate the learning of the beauty of the Macedonian language. Several professors (Simon Sazdov, Esen Bejzat, Halil Acikgjoz, Sevim Hilmioglu) reviewed the book in order to make it more useful and conformant with the criteria for this types of books
Šimić‘s Marija in Context of the Work
No full textPisac članka upozorava na stilističke, teološke i političke posljedice pojave različitih inačica teksta pjesme Marija. Članak tumači pjesmu stavljajući narav njezina adresata u surječje drugih primatelja poruka iz opusa. Autor također govori o smislu glagola iz pjesme te vezi kazivača i lika kojemu se obraća.The author shows stylistic, theological and political consequen-ces caused by the different variations of the poem Mary, Marija. The article explains the poem placing its addressee in the context of the opus. The author also illuminates the sense of the verbs and the relations between the teller and the addressee of the poem
MARIJA ŠVAJNCER, 2020: VESELJE DO ŽIVLJENJA ALI FILOZOFIJA RADOŽIVOSTI
No full textThe author presents a new scientific monograph by Marija Švajncer, entitled Joy of Life or the Philosophy of Joy (2020)
The treatment of locally advanced prostate cancer with radiotherapy and systemic therapy
No full textRak prostate je jedan od najčešćih oblika raka među muškarcima diljem svijeta. Prava etiologija nastanka tog karcinoma nije poznata iako su čimbenici poput dobi, rase, pozitivne obiteljske anamneze, genetike, pretilosti, hormona, pušenja cigareta i alkohola povezani s većom učestalošću pojavljivanja raka prostate. Lokalno uznapredovali oblik raka prostate predstavlja stadij bolesti u kojem se tumor proširio izvan prostate na okolno tkivo i/ili regionalne limfne čvorove. Liječenje lokalno uznapredovalog raka prostate je terapijski izazov zbog potencijalnog rizika od daljnjeg napredovanja bolesti i smanjene stope preživljavanja bolesnika. Moderne dijagnostičke metode poput PSMA PET/CT-a i kolin PET/CT-a imaju bitnu ulogu u što ranijem prepoznavanju proširenosti bolesti i time ranije liječenje bolesnika s posljedično boljim rezultatima u smislu duljeg preživljavanja. U ovom radu obuhvaćene su analize različitih tehnika zračenja prostate poput radioterapije vanjskim snopom zračenja (EBRT) i brahiterapije te nekoliko razvijenijih metoda zračenja . Također, su prikazani različiti modaliteti sistemske terapije koji uključuju kemoterapiju i hormonsku terapiju. Primjena antiandrogene terapije, terapije LHRH agonistima/antagonistima, docetaksela razrađena je nizom meta-analiza koje su prikazane u radu. Naglasak je stavljen na kombinaciju zračenja i sistemne terapije koji u većini slučajeva pružaju bolju kontrolu bolesti i produljuju preživljavanje bolesnika.. Ovaj diplomski rad pruža pregled najnovijih saznanja o liječenju lokalno uznapredovalog raka prostate s naglaskom na zračenje i sistemsku terapiju i pruža osnovu za daljnje istraživanje.Prostate cancer is one of the most common types of cancer among men worldwide. The exact etiology of prostate cancer is not known, although factors such as age, race, positive family history, genetics, obesity, hormones, smoking, and alcohol consumption have been associated with a higher prostate cancer incidence. Locally advanced prostate cancer represents a stage in which the tumour has spread beyond the prostate onto surrounding tissues and/or regional lymph nodes. Treating locally advanced prostate cancer poses a treatment challenge due to the potential risk of further disease progression and reduced survival rates. Modern diagnostic methods such as PSMA PET/CT and choline PET/CT play a crucial role in early identification of the cancer stage and thus, eralier treatment with subsequently better results, i.e., linger survival period. This study covers analysis of various prostate radiation techniques, such as external beam radiation therapy (EBRT) and brachytherapy, as well as several more advanced radiation methods. Additionally, different modalities of systemic therapy are presented, such as chemotherapy and hormone therapy. Usage of antiandrogen therapy, LHRH agonists/antagonists and docetaxel is elaborated through a series of meta-analyses presented in the study. Emphasis is placed on the combination of radiation and systemic therapy which in most cases provides a better disease control and prolongs patients' lifespan. This thesis provides an overview of the latest findings on the treatment of locally advanced prostate cancer, focus on radiation and systemic therapy and providing a basis for further research
Voldemars (Valdis, Walter) and Marija (Mary) Auzin
No full textBlack & white photo of Voldemars (Valdis, Walter) [1904-1972] and Marija (Mary) Auzins [1906-1994]. Mary's maiden name was Berzins. Both ZValdis and Mary were born in Latvia.15.0 Family Photos, 4.0 Latvian Immigration into Canada, 4.1.3 Third Wave Immigrants (post WWII
CONTRASTIVE GRAMMAR OF A TWO UNRELATED LANGUAGES (“CONTRASTIVE GRAMMAR OF TURKISH AND MACEDONIAN LANGUAGE” BY MARIJA LEONTIK)
No full textThe textbook “Contrastive Grammar of Turkish and Macedonian” by Marija Leontik was published in 2018. This textbook is primarily intended for the subject The Contrastive Analysis of Turkish and Macedonian language, which is mandatory for students in the first semester of the Group for Turkish Language and Literature at the Faculty of Philology, University “Goce Delchev” in Stip. The content of the grammar for both languages is presented in 220 pages divided mainly into three basic chapters: Phonetics and Phonology, Morphology and Morphosyntax and Syntax, and at the end of the Grammar are added dictionaries for grammar and linguistic terms in Turkish – Macedonian – English language and in Macedonian – Turkish – English language. The textbook also includes content, preface, list of abbreviations used in the textbook, used literature and biography of the author, and each basic chapter is further divided into several essential titles and subtitles in the field of writing.
Keywords: Contrasting grammar of Turkish and Macedonian, agglutinative language, inflectional language, teaching, dictionaries, students
MARIJA ZRNEVA’S STORYTELLING PEN
No full textThis text refers to Marija Zrneva from Voden and her writing published in the newspaper Novini. The untitled text was published in 1898 and describes the fire in the town of Voden, in chronological order, since its beginning, the fight against the fire and the successful extinguishing. According to the manner and style of the published work, as well as the structural elements of the literary narrative text, we believe that we can characterize it as the first registered Macedonian short story written by a woman, and her as the first registered author of a short story in Macedonian literature.
Keywords: Marija Zrneva, Voden, short story, 19th century, newspaper Novini, newspaper Vesti, newspaper Makedonska Dzvezda
The role of immunotherapy in the treatment of patients with metastatic kidney cancer
No full textKarcinom bubrega ubraja se među deset najčešćih zloćudnih novotvorina. Bolest može biti lokalna ili metastatska. Lokalno ograničena bolest ima znatno bolju prognozu od metastatske. Razvojem radioloških pretraga dijagnoza se sve češće postavlja u fazi lokalne bolesti. Najčešći histološki tip raka bubrega je svjetlostanični, drugi najčešći su papilarni i kromofobni. Stadij bolesti se određuje prema TNM-klasifikaciji. Prije početka liječenja metastatske bolesti treba odrediti stupanj rizika za bolesnika, koriste se MSKCC i IMDC modeli za tu svrhu. Osnovne metode liječenja metastatske bolesti su: kirurško liječenje, sustavna terapija i radioterapija. Od kirurških zahvata koriste se: citoreduktivna nefrektomija, limfadenektomija i metastazektomija. Liječenje sustavnom terapijom prije nije davalo rezultata zato što je rak bubrega kemorezistentan tumor. Razvojem novih lijekova nastaju bolje terapijske opcije. Skupine lijekova koje se danas koriste u sustavnoj terapiji uključuju: inhibitore kontrolnih točaka (imunoterapija), tirozin kinazne inhibitore, mTOR inhibitore i monoklonalna VEGF protutijela. Najbolju terapijsku opciju predstavljaju inhibitori kontrolnih točaka te tirozin kinazni inhibitori. Suvremene smjernice za liječenje prve linije metatstatskog svijetlostaničnog raka bubrega savjetuju primjenu dualne imunoterapije ili kombinirane imunoterapije s tirozin kinaznim inhibitorom. Česte su nuspojave kod primjene ovih lijekova, ali se nuspojave često smatraju biomarkerima odgovora na terapiju. Radioterapija ima primarno ulogu u palijativnom liječenju metastaza. Zahvaljujući primjeni imunoterapije najčešće u prvoj, rjeđe u drugoj liniji liječenja bolesnika s metastatskim rakom bubrega može se potpuno izliječiti oko 15% bolesnika. Liječenje metastatskog karcinoma bubrega ostaje i dalje izuzetno zahtjevno. Kod liječenja je potrebna redovita kontrola bolesnika uz multidisciplinarni pristup.Kidney cancer is one of the ten most common malignant neoplasms. The disease can be local or metastatic. Locally limited disease has a significantly better prognosis than the metastatic one. With the development of radiological tests, the diagnosis is more often made in the local disease stage. The most common histological type of renal cell carcinoma is clear cell (ccRCC), and the second most common are papillary and chromophobe. The stage of the disease is determined according to the TNM classification. Before starting the treatment of metastatic disease, the risk level for the patient should be identified, and MSKCC and IMDC models are used for this purpose. Basic treatment methods for metastatic disease are: surgical treatment, systemic therapy and radiotherapy. The following surgical procedures are used: cytoreductive ephrectomy, lymphadenectomy and metastasectomy. Treatment with systemic therapy did not provide results before because kidney cancer is a chemo-resistant tumour. By developing new drugs, better treatment options were created. Drug groups used in systemic therapy nowadays include: checkpoint inhibitors (immunotherapy), tyrosine kinase inhibitors, mTOR inhibitors and monoclonal VEGF antibodies. The best therapeutic options are checkpoint inhibitors and tyrosine kinase inhibitors. Current treatment guidelines for first-line treatment of metastatic clear cell kidney cancer propose using dual immunotherapy or combined immunotherapy with tyrosine kinase inhibitor. Side effects are common when using these drugs, but they are often considered biomarkers of therapeutic response. Radiotherapy has a role primarily in palliative treatment of metastases. By implementing immunotherapy most commonly in the first, and less often in second line of treatment of patients with metastatic kidney cancer, approximately 15% of patients can be fully cured. Treatment of metastatic kidney cancer remains extremely demanding. Treatment requires regular monitoring of the patient and a multidisciplinary approach
Neoadjuvant therapy of urothelial bladder cancer
No full textUrotelni karcinom mokraćnog mjehura zloćudna je novotvorina povezana s visokim morbiditetom i mortalitetom. Površinski oblik raka mokraćnog mjehura liječi se transuretralnom endoskopskom resekcijom, a mišićno invazivni radikalnom cistektomijom uz prethodnu neoadjuvantnu kemoterapiju (NAC) temeljenu na cisplatini. Prednosti neoadjuvantne sistemske terapije su uklanjanje mikrometastaza, postizanje boljeg patohistološkog odgovora, negativnih resekcijskih rubova i boljeg preživljenja. Dva neoadjuvantna protokola koja se najčešće primjenjuju su GC (gemcitabin, cisplatina) i ddMVAC (metotreksat, vinblastin, doksorubicin, cisplatina). Više puta su provođene usporedbe njihove učinkovitosti i oba protokola su pokazala kao rezultat liječenja potpuni patohistološki odgovor kod približno 30% bolesnika i poboljšala su petogodišnje preživljenje za 5 do 8%. Nova ispitivanja su ipak pokazala veću učinkovitost ddMVAC protokola koji se stoga preporuča po najnovijim smjernicama. Najveći problem neoadjuvantne kemoterapije je njena toksičnost. Zbog toga postoje brojni pokušaji da se unaprijed odredi koji će bolesnik imati dobar odgovor na NAC, a koji ne, ali zasad nijedan kriterij nije dovoljno precizan. Imunoterapija trenutno se primjenjuje samo u slučaju metastatskog ili lokalno uznapredovalog karcinoma kod bolesnika koji ne mogu primiti cisplatinu. Neoadjuvantna imunoterapija kao se za sada uglavnom koristi samo u kliničkim ispitivanjima. Istražuje se efikasnost inhibitora kontrolnih točaka s obećavajućim rezultatima. Za probrane bolesnike koji žele izbjeći cistektomiju postoji opcija trimodalnog liječenja koja obuhvaća TURBT, kemoterapiju i radioterapiju. Potrebno je napraviti više kliničkih ispitivanja trimodalne terapije i usporediti je s neoadjuvantnom sistemskom terapijom i radiklanom cistektomijom kako bi se odredio optimalan protokol za bolesnike s lokalnim urotelnim rakom.Urothelial bladder cancer is a malignant neoplasm linked to high morbidity and mortality. Superficial bladder cancer is treated with endoscopic treatment with transurethral resection (TURBT), and muscle‐invasive bladder cancer with radical cystectomy with prior cisplatin-based neoadjuvant chemotherapy (NAC). The advantages of neoadjuvant systemic treatment are removal of micro metastases and achievement of better pathohistological response, negative resection margins and better survival chances. Two most commonly applied NAC protocols are GC (gemcitabine, cisplatin) and ddMVAC (methotrexate, vinblastine, doxorubicin, cisplatin).
Multiple comparisons between their efficiency and both protocols have shown a complete pathohistological response in approximately 30% of patients and have increased 5-year OS by 5 – 8%. However, new trials have shown better efficacy of ddMVAC regimen which is therefore now recommended according to the latest guidelines. The biggest issue of neoadjuvant chemotherapy is its toxicity. There are multiple attempts at determining in advance which patient will or will not respond positively to NAC, but unfortunately so far none of these factors have shown as precise enough. Immunotherapy is currently used only in patients with metastatic or locally advanced cancer unsuitable for cisplatin. Neoadjuvant immunotherapy is used only in clinical trials for the time being. Checkpoint inhibitor efficiency is being investigated with promising results. For selected patients who wish to avoid cystectomy there is an option of trimodal treatment which consists of TURBT, chemotherapy and radiotherapy. To determine optimal protocol for patients with local urothelial cancer, more clinical trials for trimodal treatment need to be conducted and to compare it with neoadjuvant systemic treatment and radical cystectomy
- …
